Cephalon was directed to collect and submit additional data to attest to the drug's safety.
"We're pretty comfortable we've got an effective agent here, " says Cephalon Chief Executive FrankBaldinoFrank Baldino.
Cephalon trades for 32 times latest 12-month profits and 27 times estimated 2003 earnings.
Another potentially bullish sign is that short interest in Cephalon has been extraordinarily high.
In June 2009, the general counsel testified that Watson had not entered into an agreement with Cephalon.
FORBES: One Federal Agency��s Crusade Against Patent Litigation Settlements
"Provigil is obviously the big drug and did the heavy lifting, " says Cephalon spokesman Robert W. Grupp.
Cephalon has applied to the U.S. Food and Drug Administration to approve the drug for more indications.
That could benefit Cephalon (nasdaq: CEPH - news - people ), of Frazer, Pa.
"We're pretty comfortable we've got an effective agent here, " says Cephalon Chief Executive Frank Baldino .
Doctors said that numerous other companies, including Novartis, Ariad and Cephalon are working on ALK blocking drugs.
FORBES: Pfizer Drug Powers Cancer Treatment Into The DNA Age
Side effects were the main reason for an FDA advisory panel's March 23 vote against Cephalon 's Sparlon.
But the very engine that launched Cephalon on a rocketlike ascent five years ago has some analysts worried.
As drizzle falls on Cephalon's ceph (nasdaq: ceph - news - people) offices in West Chester, Pa.
Cephalon has a fantastic drug in Provigil, which is already a successful narcolepsy drug and will soon treat other illnesses.
Thus, for example, a federal district court recently threw out a stockholder derivative suit filed against the directors of Cephalon, Inc.
FORBES: Courts Should Firmly Reject Shareholder Activists' Breach of Fiduciary Duty Derivative Suits
The buys among the top ten profitability performers are Verisign, Cliff Natural Resources, KLA-Tencor and Cephalon Inc.
FORBES: Cephalon, KLA-Tencor Stand Out Among Top Profitability Performers
Apparently, many investors were expecting Cephalon's wonder drug, brought to market last February as a narcolepsy treatment, to treat ADHD as well.
We are pleased to see some of this work reflected in an important new law review article authored by former Cephalon, Inc.
FORBES: The Dangers Of Information Restrictions On Drugs' Off-Label Uses
Instead, generics will be kept at bay until 2011, allowing Cephalon to fund further studies to rekindle physician interest in the medicine.
All four carry low valuations within their industries, from the 6th percentile for Cephalon up to just the 35th percentile for KLA-Tencor.
FORBES: Cephalon, KLA-Tencor Stand Out Among Top Profitability Performers
Cephalon (nasdaq: CEPH - news - people ) sells a drug called Trisenox to treat a form of leukemia.
Cephalon sells a drug called Trisenox to treat a form of leukemia.
Cephalon is a biopharmaceutical company that we have highlighted in the past, and they reported another outstanding quarter after the close on Tuesday.
Yet, despite these other, potentially lucrative markets, Cephalon is prohibited from marketing the drug for any illness besides narcolepsy, the only approved indication.
Biopharmaceutical firm Cephalon reported first quarter results on Tuesday afternoon that proved the company is off to a solid start in 2010.
Not only was last quarter a successful one for Cephalon, but they also raised full year earnings guidance for the second straight quarter.
For instance, one settlement with multiple generic firms is expected to give biotech Cephalon several extra years of sales of its wakefulness drug Provigil.
In addition to the regular reporting on operations, Cephalon also unveiled their best estimates as far as how healthcare reform will affect their business.
Cephalon is riding high on the prospects for Provigil, Sparlon and Nuvigil, a stay-awake drug that is effective for ten hours, compared with Provigil's six.
At Ockham, we are reaffirming our Undervalued stance on Cephalon as of this week as the company is off to a very strong start.
应用推荐